- Home
- ECBK vs IMUX Comparison
ECBK vs IMUX Comparison
Compare ECBK & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECBK | IMUX |
|---|---|---|
| Founded | 1919 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.5M | 155.8M |
| IPO Year | 2022 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ECBK | IMUX |
|---|---|---|
| Price | $19.69 | $6.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $43.09 |
| AVG Volume (30 Days) | 7.1K | ★ 417.3K |
| Earning Date | 10-30-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 95.83 | 38.00 |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $598,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.78 | ★ N/A |
| Revenue Growth | ★ 3.64 | N/A |
| 52 Week Low | $15.16 | $0.51 |
| 52 Week High | $21.78 | $17.43 |
Technical Indicators
Market Signals| Indicator | ECBK | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 38.80 | 28.28 |
| Support Level | $19.11 | $0.83 |
| Resistance Level | $20.05 | $8.60 |
| Average True Range (ATR) | 0.54 | 0.69 |
| MACD | -0.11 | 0.04 |
| Stochastic Oscillator | 19.46 | 17.84 |
Price Performance
Historical ComparisonAbout ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company. The firm, through its subsidiary, engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, multifamily real estate loans, construction and land loans, and home equity lines of credit.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.